Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$53.82

-3.83 (-6.64%)

, ANTM

Anthem

$120.84

-1.06 (-0.87%)

13:13
10/12/16
10/12
13:13
10/12/16
13:13

Anthem says policy unchanged on Sarepta's Exondys 51, Bloomberg reports

Bloomberg cites an emailed comment from an Anthem spokesperson.

SRPT

Sarepta

$53.82

-3.83 (-6.64%)

ANTM

Anthem

$120.84

-1.06 (-0.87%)

  • 02

    Nov

  • 06

    Nov

SRPT Sarepta
$53.82

-3.83 (-6.64%)

10/07/16
BARD
10/07/16
NO CHANGE
Target $102
BARD
Outperform
Anthem policy does not mean insurer not covering Sarepta drug, says Baird
Baird analyst Brian Skorney noted Anthem (ANTM) has categorized Sarepta (SRPT) Duchenne muscular dystrophy drug Exondys 51 as "not medically necessary" in a new coverage policy, but he cautions this "does not mean that Anthem is not covering the drug." The analyst explains that the policy means prior authorization requirements may be stricter, but he "highly doubts" that eligible patients will be denied coverage. Skorney, who adds that other large insurers appear to have favorable coverage for the drug, keeps an Outperform rating and $102 price target on Sarepta shares.
10/05/16
ADAM
10/05/16
NO CHANGE
Target $28
ADAM
Buy
Summit Therapeutics price target raised to $28 from $14 at Canaccord
Canaccord analyst Arinda Lee raised her price target on Summit Therapeutics (SMMT) to $28 from $14 following the announcement of its collaboration and licensing agreement with Sarepta Therapeutics (SRPT). The deal calls for Sarepta to gain EU commercialization rights to Summit's pipeline of oral utrophin modulators for all patients with Duchenne muscular dystrophy. Lee reiterated her Buy rating Summit Therapeutics shares.
10/04/16
PIPR
10/04/16
NO CHANGE
Target $68
PIPR
Overweight
Piper Jaffray ups Sarepta target to $68 on Summit deal
Piper Jaffray analyst Edward Tenthoff raised his price target for Sarepta Therapeutics (SRPT) to $68 from $64 after the company licensed Summit Therapeutics' (SMMT) ezutromid to treat Duchenne Muscular Dystrophy in Europe, Turkey and the Commonwealth of Independent States. The deal is a smart way for Sarepta to capitalize on its lead in DMD with the recent FDA approval of Exondys51, Tenthoff tells investors in an intraday research note. His new price target of $68 reflects the value of ezutromid. Tenthoff reiterates an Overweight rating on Sarepta. The stock is up 1% to $61.61 in late morning trading. Summit is up 94%, or $8.17, to $16.82.
09/28/16
JMPS
09/28/16
NO CHANGE
JMPS
Street underestimating price of Sarepta drug, says JMP Securities
JMP Securities analyst Liisa Bayko expects the price of Sarepta's Exondys 51 drug will be above the company's projected annual net price of $300,000. She thinks that the price will come in "closer to $538,000 per year on a gross basis, $457,000 net of discounts and compliance." The analyst raised her price target on the shares to $90 from $60 and keeps an Outperform rating on the stock.
ANTM Anthem
$120.84

-1.06 (-0.87%)

09/22/16
EVER
09/22/16
INITIATION
Target $133
EVER
Hold
Anthem initiated with a Hold at Evercore ISI
Evercore ISI initiated Anthem with a Hold and a $133 price target.
09/20/16
BOFA
09/20/16
NO CHANGE
BOFA
Anthem removed from US 1 List at BofA/Merrill
09/13/16
JEFF
09/13/16
DOWNGRADE
Target $138
JEFF
Hold
Anthem downgraded to Hold from Buy at Jefferies
Jefferies analyst David Windley downgraded Anthem (ANTM) to Hold from Buy saying the restoration of some of the company's expense cuts could limit 2017 earnings growth. "The belt-tightening also potentially signals under-investment in the platform," Windley tells investors in a research note. He sees a lack of catalysts for Anthem shares and cut his price target to $138 from $156. The health benefit company closed yesterday up $1.63 to $128.58. In Managed Care, Windley's top pick is UnitedHealth (UNH). The company has an attractive valuation and "best-in-class" management team, Windley argues. He has a Buy rating on UnitedHealth with a $163 price target.
08/25/16
COWN
08/25/16
NO CHANGE
COWN
Managed Care mergers unlikely to close, says Cowen
Cowen analyst Christine Arnold believes the current managed care mergers including Aetna (AET) and Humana (HUM) and Anthem (ANTM) and Cigna (CI) are unlikely to close. The analyst said the government's ability to appeal could extend the litigation process beyond the termination dates stipulated in the merger agreements. Arnold believes the Aetna/Humana merger has a better chance of closing relative to the Anthem/Cigna deal, but believes neither are likely to close.

TODAY'S FREE FLY STORIES

CPB

Campbell Soup

$59.00

0.72 (1.24%)

10:21
12/09/16
12/09
10:21
12/09/16
10:21
Options
Campbell Soup calls are stirring »

Campbell Soup calls are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RH

Restoration Hardware

$32.75

-6.24 (-16.00%)

10:20
12/09/16
12/09
10:20
12/09/16
10:20
Options
Restoration Hardware options active as shares fall on earnings »

Restoration Hardware…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

10:20
12/09/16
12/09
10:20
12/09/16
10:20
General news
Treasury Action: yields remained subdued »

Treasury Action: yields…

CPK

Chesapeake Utilities

$68.55

0.55 (0.81%)

, CNX

CONSOL

$21.16

-0.62 (-2.85%)

10:19
12/09/16
12/09
10:19
12/09/16
10:19
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…click here.

CPK

Chesapeake Utilities

$68.55

0.55 (0.81%)

CNX

CONSOL

$21.16

-0.62 (-2.85%)

JCI

Johnson Controls

$43.68

0.03 (0.07%)

AMID

American Midstream Partners

$16.95

-0.05 (-0.29%)

BIP

Brookfield Infrastructure

$32.93

0.2499 (0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

ANF

Abercrombie & Fitch

$15.96

-0.28 (-1.72%)

, DLTH

Duluth Holdings

$37.04

3.09 (9.10%)

10:19
12/09/16
12/09
10:19
12/09/16
10:19
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…click here.

ANF

Abercrombie & Fitch

$15.96

-0.28 (-1.72%)

DLTH

Duluth Holdings

$37.04

3.09 (9.10%)

DTEA

DAVIDsTEA

$9.30

0.15 (1.64%)

HLT

Hilton

$26.54

0.295 (1.12%)

HZNP

Horizon Pharma

$15.03

-4.36 (-22.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 14

    Dec

AZN

AstraZeneca

$27.11

0.84 (3.20%)

, ADSK

Autodesk

$81.74

1.4 (1.74%)

10:19
12/09/16
12/09
10:19
12/09/16
10:19
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…click here.

AZN

AstraZeneca

$27.11

0.84 (3.20%)

ADSK

Autodesk

$81.74

1.4 (1.74%)

ETN

Eaton

$69.45

0.47 (0.68%)

FLR

Fluor

$56.77

0.77 (1.38%)

SYY

Sysco

$54.46

0.13 (0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

  • 09

    Jan

  • 16

    Feb

$NYE

NYSE Market Internals

10:16
12/09/16
12/09
10:16
12/09/16
10:16
Technical Analysis
NYSE market internals summary »

Breadth is bullish across…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

10:16
12/09/16
12/09
10:16
12/09/16
10:16
Technical Analysis
NASDAQ market internals summary »

Volume is light for this…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATH

Athene Holding

10:15
12/09/16
12/09
10:15
12/09/16
10:15
Syndicate
Breaking Syndicate news story on Athene Holding »

Athene Holding indicated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

10:15
12/09/16
12/09
10:15
12/09/16
10:15
General news
FX Action: The dollar »

FX Action: The dollar…

SDRL

Seadrill

$3.72

0.315 (9.26%)

10:14
12/09/16
12/09
10:14
12/09/16
10:14
Options
Seadrill calls active as shares rally »

Seadrill calls active as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VHC

VirnetX

$3.35

0.05 (1.52%)

10:12
12/09/16
12/09
10:12
12/09/16
10:12
Periodicals
Breaking Periodicals news story on VirnetX »

Appeals court affirms…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATH

Athene Holding

10:10
12/09/16
12/09
10:10
12/09/16
10:10
Syndicate
Breaking Syndicate news story on Athene Holding »

Athene Holding indicated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

XLF

Financial Select Sector

$23.63

-0.07 (-0.30%)

10:10
12/09/16
12/09
10:10
12/09/16
10:10
Options
$15.9M premium block in SPDR Financials »

$15.9M premium block in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:10
12/09/16
12/09
10:10
12/09/16
10:10
General news
U.S. December consumer sentiment surged 4.2 points to 98.0 in preliminary »

U.S. December consumer…

TEX

Terex

$32.28

-0.06 (-0.19%)

10:09
12/09/16
12/09
10:09
12/09/16
10:09
Upgrade
Terex rating change  »

Terex upgraded to Mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

AZN

AstraZeneca

$27.09

0.82 (3.12%)

10:08
12/09/16
12/09
10:08
12/09/16
10:08
Hot Stocks
FDA accepts BLA for AstraZeneca's durvalumab for bladder cancer »

AstraZeneca and its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

KO

Coca-Cola

$41.82

0.835 (2.04%)

10:04
12/09/16
12/09
10:04
12/09/16
10:04
Technical Analysis
Coca-Cola tests downtrend resistance »

The stock was last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

10:01
12/09/16
12/09
10:01
12/09/16
10:01
General news
Wholesale Trade Inventories data reported »

October Wholesale Trade…

10:01
12/09/16
12/09
10:01
12/09/16
10:01
General news
Consumer Sentiment Index data reported »

Consumer Sentiment Index…

LVS

Las Vegas Sands

$56.77

2.1 (3.84%)

10:00
12/09/16
12/09
10:00
12/09/16
10:00
Options
Sweep call buyer in LVS »

Sweep call buyer in LVS.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATH

Athene Holding

10:00
12/09/16
12/09
10:00
12/09/16
10:00
Syndicate
Breaking Syndicate news story on Athene Holding »

Athene Holding indicated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

CFX

Colfax

$39.53

0.25 (0.64%)

10:00
12/09/16
12/09
10:00
12/09/16
10:00
Options
Colfax Dec 40 calls trade for 65 and 70c »

Colfax Dec 40 calls trade…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAL

American Airlines

$48.05

-0.6 (-1.23%)

, BIIB

Biogen

$289.54

4.24 (1.49%)

09:55
12/09/16
12/09
09:55
12/09/16
09:55
Options
Early notable gainers among liquid option names on December 9th »

Notable gainers among…

AAL

American Airlines

$48.05

-0.6 (-1.23%)

BIIB

Biogen

$289.54

4.24 (1.49%)

UAL

United Continental

$75.65

2.91 (4.00%)

AVGO

Broadcom

$170.71

2.16 (1.28%)

AGN

Allergan

$193.38

4.91 (2.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:55
12/09/16
12/09
09:55
12/09/16
09:55
Conference/Events
JPMorgan aerospace & defense analyst holds an analyst/industry conference call »

Aerospace & Defense…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.